Safety reference
Peptide Side Effects: Reported Adverse Events by Compound
Research-frame reference for reported adverse events across 8 peptides. Three lenses: per-compound vertical, mechanism-class horizontal, and cross-compound shared. Educational only; not medical advice.
Eight compounds, most common reported effect
- Retatrutide: nausea reported in roughly 30 percent at 12mg/wk (Phase 2).
- Tirzepatide: nausea reported in roughly 30 percent at 15mg/wk (Phase 3 SURMOUNT-1).
- BPC-157: injection-site reactions reported; pro-angiogenic theoretical caveat.
- TB-500: injection-site reactions, headache, transient fatigue reported.
- KLOW Combo: inherits component profiles (BPC + TB-500 + GHK-Cu + KPV).
- CJC-1295/Ipamorelin: water retention, tingling, IGF-1 elevation reported.
- GHK-Cu: Wilson disease absolute contraindication; injection-site reactions.
- MOTS-c: well-tolerated in small human studies; long-term safety not established.
How to read this page
Three lenses. Cross-reference against the glossary for term definitions.
Lens 1: Per-compound
Vertical view. One card per compound listing reported events with trial or registry citation.
Lens 2: Mechanism class
Horizontal cut. GLP-1 class, GH-axis class, tissue-repair class shared profiles.
Lens 3: Cross-compound
Single table showing which effects show up across multiple SKUs.
Methodology note
Effect-rate percentages reported on this page come from registered Phase 2 and Phase 3 clinical trials with citation in the originating sentence. BPC-157, TB-500, KLOW Combo, CJC-1295/Ipamorelin, GHK-Cu, and MOTS-c lack large registered human trials; reported-event language for those compounds is qualitative (reported, rarely reported) rather than quantitative. Absence of a reported effect does not imply zero risk.
Per-compound profiles
Eight cards, one per compound. Reported events with trial citation. Glossary anchors for each term.
Retatrutide
Phase 2 trial (NEJM 2023). Phase 3 ongoing (TRIUMPH program). Research compound, not FDA-approved.
GLP-1 class shared profile reported in Phase 2 (Jastreboff et al, NEJM 2023): nausea around 30 percent at 12mg/wk cohort, vomiting, diarrhea, constipation, decreased appetite. Reported effects are dose-dependent and most pronounced during titration.
Glossary
Tirzepatide
Phase 3 SURMOUNT-1 (NEJM 2022). FDA-approved as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023). Research vial sold by Peptara.
GLP-1 / GIP class shared profile reported in Phase 3 SURMOUNT-1 (Jastreboff et al, NEJM 2022): nausea around 30 percent at 15mg/wk, diarrhea, constipation, vomiting. Lower hypoglycemia rate than semaglutide in head-to-head SURPASS-2 (T2D context). Black-box warning for thyroid C-cell tumors per the FDA-approved Mounjaro / Zepbound label.
Glossary
BPC-157
Research compound. Preclinical literature deep; large registered human trials absent.
Research compound with no large registered human trials. Reported preclinical effects centered on pro-angiogenic and cytoprotective activity (Sikiric et al, multiple journals, 1990s to 2020s). Reported user-reported events: mild injection-site reactions, transient nausea. Theoretical tumor-angiogenesis concern from the pro-angiogenic mechanism; not confirmed in humans. Discuss with a clinician if there is an active or recent malignancy diagnosis.
Glossary
TB-500
Research compound. Thymosin beta-4 parent molecule has human cardiac and corneal trial data; TB-500 fragment specifically lacks large registered human trials.
Thymosin beta-4 fragment, research compound. Reported user-reported events: injection-site reactions, headache, transient fatigue. Same theoretical tumor-angiogenesis caveat as BPC; not human-confirmed at typical research doses. WADA-banned in competitive sport.
Glossary
KLOW Combo
Peptara stack formulation. Individual components have separate research bases; the blend itself is not the subject of registered trial literature.
Peptara-formulated 4-peptide blend (BPC-157 + TB-500 + GHK-Cu + KPV). Reported events inherit from each component. Cross-reference the per-compound cards above for BPC, TB-500, and GHK-Cu reported events; KPV is generally anti-inflammatory and well-tolerated in small human studies.
Glossary
CJC-1295/Ipamorelin
CJC-1295 and Ipamorelin separately appear in endocrinology research; the blend is not an FDA-approved finished pharmaceutical.
GH-axis. Reported effects: water retention or edema (typically transient first 2 to 3 weeks), tingling in extremities, transient drop in fasting glucose, IGF-1 elevation. Long protocols warrant IGF-1 lab monitoring. Retinopathy risk worth discussing in diabetic users per GH-class signal in SUSTAIN-6 (semaglutide) and general GH-axis literature.
Glossary
GHK-Cu
Strongest dermatology and wound-healing literature among the 8 compounds on this page (Pickart et al series). Not FDA-approved as a finished pharmaceutical.
Copper peptide. Reported events: copper accumulation in patients with Wilson disease (absolute contraindication), mild injection-site reactions, transient skin flushing. Some users report blue-tinted skin discoloration at injection sites (copper-related, reversible). Topical formulations rarely irritate; long high-dose systemic protocols carry a theoretical copper accumulation caveat.
Glossary
MOTS-c
Research compound. Preclinical plus small human studies; no Phase 3 obesity or metabolic trial.
Mitochondrial peptide. Limited human data. Reported in small human studies and preclinical work (Lee et al, Cell Metab 2015): well-tolerated, no significant adverse events at typical research doses. Long-term human safety not established.
Glossary
Mechanism-class shared profiles
Three biological classes, three shared profiles.
GLP-1 class
Reta + Tirz (Sema reference)
- Nausea (around 30 percent at peak doses, Phase 2/3)
- Diarrhea, constipation, vomiting
- Decreased appetite (intended effect)
- Hypoglycemia risk when stacked with insulin or sulfonylureas
- FDA black-box warning for MTC and MEN2 (Tirz; reta class-relevant)
- Rare pancreatitis, gallbladder events
- Gastroparesis reported (semaglutide signal)
- Retinopathy signal in SUSTAIN-6 (semaglutide; class consideration)
GH-axis class
CJC-1295/Ipamorelin (Tesamorelin class peer)
- Water retention or edema (typically transient)
- IGF-1 elevation (monitor labs on long protocols)
- Tingling in extremities (carpal-tunnel-like)
- Fasting glucose changes
- Retinopathy risk in diabetic users
- Joint discomfort reported
Tissue-repair class
BPC-157 + TB-500 + KLOW + GHK-Cu
- Angiogenesis caveat: theoretical tumor risk, not human-confirmed
- Injection-site reactions reported (most common AE class)
- Transient headache, mild fatigue
- Lack of large registered human trials
- Wilson disease absolute contraindication (GHK-Cu specifically)
- WADA-banned status for TB-500 (athletes)
Cross-compound shared effects
Which effects show up across multiple SKUs. Lookup format.
| Effect | Reta | Tirz | BPC | TB | KLOW | CJC | GHK | MOTS |
|---|---|---|---|---|---|---|---|---|
| Nausea | High | High | Rare | Rare | Rare | - | - | - |
| Injection-site reaction | Reported | Reported | Common | Common | Common | Common | Common | Rare |
| Headache | Reported | Reported | - | Reported | Reported | Reported | - | - |
| Fatigue | Reported | Reported | - | Reported | Reported | Reported | - | - |
| Water retention | - | - | - | - | - | Common | - | - |
| GI distress | High | High | Rare | Rare | Rare | - | - | - |
| Hypoglycemia (with insulin) | Possible | Possible | - | - | - | Possible | - | - |
| IGF-1 elevation | - | - | - | - | - | Reported | - | - |
Reported means the effect appears in trial registry or user-reported registry. Absence ("-") does not imply zero risk. High and Common are qualitative bands; see per-compound cards above for citations.
Contraindications by compound
Per-SKU absolute and relative contraindications, pregnancy notes, and drug interactions worth flagging.
| Compound | Absolute | Relative | Pregnancy | Interactions |
|---|---|---|---|---|
| Retatrutide | Personal or family history of MTC, MEN2 | Active pancreatitis, severe GI disease | Not recommended (research compound, no human pregnancy data) | Insulin, sulfonylureas (hypoglycemia risk) |
| Tirzepatide | Personal or family history of MTC, MEN2 | Active pancreatitis, gastroparesis, severe diabetic retinopathy | Not recommended (Wegovy / Zepbound labels) | Insulin, sulfonylureas, oral drugs with narrow therapeutic index (delayed absorption) |
| BPC-157 | None established; theoretical caveat with active malignancy | Active or recent cancer diagnosis (pro-angiogenic mechanism) | Not recommended (research compound, no human pregnancy data) | None well-documented |
| TB-500 | None established; theoretical caveat with active malignancy | Active or recent cancer diagnosis, competitive athletes (WADA-banned) | Not recommended (research compound, no human pregnancy data) | None well-documented |
| KLOW Combo | Wilson disease (per GHK-Cu component) | Inherits all component cautions; active malignancy | Not recommended (research compound, no human pregnancy data) | None well-documented |
| CJC-1295/Ipamorelin | Active malignancy, active diabetic retinopathy | Type 2 diabetes (monitor glucose), hypothyroidism | Not recommended (research compound, no human pregnancy data) | Insulin, sulfonylureas (hypoglycemia risk), corticosteroids |
| GHK-Cu | Wilson disease | Severe hepatic impairment (copper handling) | Not recommended (research compound, no human pregnancy data) | Other copper-containing supplements |
| MOTS-c | None established | Long-term human safety not established | Not recommended (research compound, no human pregnancy data) | None well-documented |
Wilson disease alert
GHK-Cu and KLOW Combo (which contains GHK-Cu) carry an absolute contraindication in Wilson disease, a genetic disorder of copper metabolism. See the Wilson disease glossary entry.
Severity grading
Common Terminology Criteria for Adverse Events (CTCAE) is the 5-grade scale used in registered trials and increasingly in peptide research. Reference the CTCAE grading glossary entry.
| Grade | Severity | Example |
|---|---|---|
| Grade 1 | Mild | Mild nausea, loss of appetite without weight loss |
| Grade 2 | Moderate | Oral intake decreased without significant weight loss; outpatient intervention |
| Grade 3 | Severe | Inadequate oral caloric or fluid intake; tube feeding, hospitalization indicated |
| Grade 4 | Life-threatening | Urgent intervention indicated; ICU-level care |
| Grade 5 | Death | Death related to adverse event |
When to stop and seek care
Generic safety triage by symptom severity, not by compound.
Stop dosing and contact a healthcare provider if any of these occur
- Severe abdominal pain (consider pancreatitis on GLP-1 class)
- Persistent vomiting with signs of dehydration
- Severe allergic reaction (hives, swelling, difficulty breathing)
- Vision changes on GH-axis peptides (consider retinopathy)
- Severe hypoglycemia (especially with insulin or sulfonylurea co-administration)
- Signs of jaundice or right-upper-quadrant pain (consider gallbladder)
- Lump or swelling in the neck (consider thyroid, especially on Tirzepatide)
- Any unusual symptom that is severe, persistent, or rapidly worsening
This is not medical advice. Educational only. If you suspect a serious adverse event, contact a qualified healthcare provider.
Reporting adverse events
For FDA-approved drugs (Mounjaro, Zepbound, Ozempic, Wegovy), report to FDA MedWatch. Research compounds have no formal reporting pathway. Peptara customers can WhatsApp the protocol team to log any reported event into the internal pharmacovigilance log; this is voluntary but useful for community-level signal detection. Reference the pharmacovigilance glossary entry.
Next steps
Glossary cross-reference
120 terms in pharmacology, dosing, reconstitution, safety, regulatory, and mechanism. Every glossary anchor on this page links there.
Open glossary
Peptides for fat loss
Ranked guide to fat-loss peptides by trial effect size. Reta, Tirz, Sema, Tesa, MOTS-c, SLU-PP-332.
Open hub
Peptides for recovery
Use-case-ranked guide to recovery peptides. BPC, TB-500, KLOW, CJC-Ipa, GHK-Cu.
Open hub
Frequently asked questions
Report a reported event
Experienced an unexpected effect? Message the Peptara team on WhatsApp to log it.
Voluntary; useful for community-level signal detection on research compounds. If a serious adverse event occurs, contact a qualified healthcare provider immediately. Educational only; not medical advice.
Educational only. Not medical advice. Reported events are aggregated from trial registries and published literature. Consult a qualified healthcare provider before any peptide use.